Biotech Strategy Blog
Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy
-
A novel approach to targeting BRAF and KRAS mutant cancers
-
Update on Amgen’s KRAS inhibitor in solid tumours
-
Targeting KRAS – Highlights from WCLC 2019
-
Can a new class of agents therapeutically target the MYC or RAS oncogenes?
-
Gerard Evan discusses inflammation and immune suppression in cancer
-
Why does Myc drive out T cells?
-
Through the window on the MYC oncogene
-
A look at Amgen’s early oncology pipeline
-
Challenges of targeting KRASG12C and why Amgen’s AMG 510 may not be a winner
-
TKIs are still alive and kicking!